Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 92 for “"Prostate specific membrane antigen"”.
-
Development and evaluation of radioimaging agents targeting prostate-specific membrane antigen
Prostate-specific membrane antigen (PSMA) is a transmembrane protein with an extracellular catalytic site that hydrolyzes N-acetylaspartate glutamate. It is associated with many solid cancers, and most notably prostate cancer as per its namesake. Moreover, PSMA expression correlates with prostate …
-
Biochemical and Molecular Characterization of the Prostate-Specific Membrane Antigen (PSMA)
Prostate cancer is the most common malignancy and the second leading cause of cancer death in males in the United States. Additionally, the number of deaths attributed to prostate cancer is increasing at a rate of approximately 8% a year. Development of new diagnostic and therapy strategies are …
-
Prostate Specific Membrane Antigen (PSMA): Immunoassay Development and Characterization of Transcriptional Regulation
Prostate cancer (PCA) is the most common cancer and the second leading cause of death among American men. The high mortality is greatly attributed to the lack of early detection tools and effective treatment for metastasis and relapses. Biomarkers that can discriminate benign from malignant tumor …
-
Changes in prostate-specific membrane antigen (PSMA) expression following ionizing irradiation - Implications for prostate cancer therapy
… the treatment of metastatic castration-resistant prostate cancer (mCRPC). The radiopharmaceutical targets prostate-specific membrane antigen (PSMA), which is overexpressed in prostate cancer (PC). The outcomes of PSMA-TRT are highly dependent on the level of PSMA expression on the surface of the …
-
Development of bispecific prostate-specific membrane antigen/fibroblast activation protein (PSMA/FAP) - targeting radiotracers for prostate cancer imaging
… targeted therapies or probes against the specific molecular drivers of tumors in individual patients. Molecular imaging has been playing a major role in personalized cancer management, including detection, staging, and treatment response assessment. However, tumor heterogeneity limits the …
-
Folate conjugated hyperbranched polyester nanoparticles for prostate tumor-targeted delivery of a cytotoxic peptide via prostate specific membrane antigen
Prostate Cancer is the second most deadly cancer in men, after lung cancer. The need for new and effective therapeutics that can constrain prostate cancer progression are challenged by the lack of suitable delivery strategies that target prostate cancer tissue. To study CT20p as potential …
-
EVALUATION OF NEW PROBES AND APPROACHES FOR CORRELATING OPTICAL AND NUCLEAR IMAGING: APPLICATIONS IN CANCER DETECTION AND TREATMENT
… nuclear) and therapy of cancer were evaluated. Specifically isostructural [2+1] Re/Tc complexes, a porphyrin conjugate and an antibody-recruiting small molecule construct capable of targeting prostate specific membrane antigen (PSMA) were assessed.</p> <p>The isostructural [2+1] metal complexes …
-
Multifunctional Iron Platinum Stealth Immunomicelles: Targeted Imaging and Therapy of Prostate Cancer
In the United States, prostate cancer is the second most common reason for cancer death in men. No imaging methods currently exist which are specific for detecting, imaging, and treating extracapsular or metastatic prostate cancer. The goal of this research was to develop novel nanoparticles that …
-
GRPR-/PSMA- dual targeted radiopharmaceutical heterodimers : theranostics in prostate cancer
[EMBARGOED UNTIL 08/01/2026] Prostate cancer remains a leading cause of cancer-related morbidity, driving the need for improved diagnostic and therapeutic tools. Heterobivalent radiopharmaceuticals, which target single- or multi-targetable receptors simultaneously, offer a promising strategy to …
-
Exploring the Anti-PSMA CAR T Cell Therapy in Treating Rhabdoid Tumor and Prostate Cancer
… tumors and metastatic castration-resistant prostate cancer (mCRPC) are difficult-to-treat malignancies due to their resistance to current therapies and their immunosuppressive tumor microenvironments. In this thesis, we explored the use of Chimeric Antigen Receptor (CAR) T cell therapy, …
-
Understanding the mechanism of 177Lu- PSMA617 radioligand therapy and evaluating its potential role in the treatment of metastatic castrate resistant prostate cancer (mCRPC)
Prostate cancer is the most common cancer in men and the third leading cause of cancer-related deaths in Canadian men. Despite hormone and radiation therapies, most patients progress to late-stage metastatic castrate-resistant prostate cancer (mCRPC). 177Lu-PSMA617 radioligand therapy (rLT) is a …
-
Metal Complexes with Tripodal and Chelating Thiourea Ligands towards Nuclear Medical Imaging
Prostate cancer is one of the most widespread types of cancer in men and at the forth position of common cancer types in 2018 according to the World Health Organization report of 2020. The prostate-specific membrane antigen (PSMA) is highly expressed on prostate cancer cells and it is the important …
-
Targeted Stimuli-Responsive Carriers for Efficient Delivery of Chemotherapeutic Drugs
… moieties such as, neuropilin-1 peptide and prostate-specific membrane antigen agonist. We prepared redox-sensitive targeted polymersomes encapsulating the hydrophobic chemotherapeutic drug in the treatment of cancer cells, including cancer stem cells. Different formulation of targeted …
-
Radionuclide therapy in advanced prostate cancer: from pain killer to disease modifier and beyond
The use of radionuclide therapy in prostate cancer has been a key focus of my research over the past 22 years. During that time, the use of radionuclide therapy in the treatment of metastatic disease has steadily increased. The initial wave of radionuclides used in prostate cancer were based on the …
-
DEVELOPING TARGETING AGENTS AND ADVANCED IMAGING TECHNIQUES FOR CANCER AND MOLECULAR IMAGING
… The initial focus is on neuroendocrine prostate cancer (NEPC), an aggressive subtype of prostate cancer. We explore the therapeutic potential of anti-CEACAM5 antibodies, demonstrating their selective targeting and inhibition of NEPC cells, suggesting a promising new therapy. Building on …
-
BIS-MPA DENDRIMERS AS A PLATFORM FOR MOLECULAR IMAGING APPLICATIONS
… dipeptide, representing a hydrophilic prostate specific membrane antigen targeting vector, demonstrated excellent affinity in vitro. The lead compound, a G2 dendrimer bearing four PSMA targeting vectors attached via an alkyl spacer was further investigated in vitro and in vivo. …
-
Targeting CD133 In Androgen Receptor Indifferent, Neuroendocrine Differentiated Aggressive Variant Prostate Cancer
… non-androgen receptor (AR) driven form of prostate cancer (PCa) known as aggressive variant prostate cancer (AVPC). Therapeutic options for AVPC are limited, and the development of novel therapeutics is significantly hindered by the inability to accurately monitor the disease through …
-
PSMA-SPECIFIC ANTIBODY FRAGMENTS FOR PROSTATE CANCER IMAGING AND THERAPY
… Fv (scFv) for molecular imaging and therapy of Prostate Cancer. The target of this scFv is the Prostate Specific Membrane Antigen (PSMA), a type II transmembrane protein overexpressed in advances stages of this disease. In the past we have generated the murine antibody D2B recognizing hPSMA, …
-
Unravelling the role of PSMA in prostate cancer while assessing the value of PSMA as a novel nano-therapy target
Prostate cancer (PCa) is the most common cancer among men in the UK, and while the disease remains localised, radiotherapy represents a major curative treatment modality. In recent years a spotlight has focused on the potential of prostate specific membrane antigen (PSMA) as a disease specific …
Page 1 of 5